Search results
Results from the WOW.Com Content Network
Keytruda slashed the risk of death by 21% over placebo in hepatocellular carcinoma patients in Asia who had previously received sorafenib. Merck's Keytruda also beat placebo at shrinking tumors ...
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
The role of keytruda in the intention-to-treat population remains uncertain at this time. In the U.S., Lynparza has three approved indications in ovarian cancer. Keytruda is not approved to treat ...
Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer ...
Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval. The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents.
Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...
Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, the risk of muscle damage exists. Nicotinic acid, like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%. Niacin may cause hyperglycemia and may also cause liver damage.
Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless ...